Delivery Order SPE2DB20D3303-SPE2DB25FA2ZK
- Not listed
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $1,466.94 to AmerisourceBergen Drug Corp for LINZESS 72 MCG capsules (30-count unit) on July 14, 2025, with an ultimate completion date of July 15, 2025. This firm fixed price delivery order was competitively awarded with no set-aside designation and will be performed at the awardee's corporate office location in Conshohocken, Pennsylvania. LINZESS is a prescription medication used to treat irritable bowel syndrome with...
- The Defense Logistics Agency awarded a $3,612.68 delivery order to AmerisourceBergen Drug Corp for LINZESS 290 microgram capsules (30-count units) on July 22, 2025, with an ultimate completion date of July 23, 2025. This competitively awarded, firm fixed-price contract contains no set-aside designation and will be performed at the contractor's corporate office location in Conshohocken, Pennsylvania. LINZESS is a prescription medication used to treat chronic idiopathic constipation and...
- The Defense Logistics Agency awarded a $1,678.18 delivery order to AmerisourceBergen Drug Corp for LINZESS 145 microgram capsules (30-count units) on August 12, 2025, with completion targeted for August 13, 2025. This firm fixed-price delivery order was competitively awarded with no set-aside designation and is being performed at the awardee's facility in Conshohocken, Pennsylvania. The contract falls under AmerisourceBergen Drug Corp's larger Indefinite Delivery Contract with DLA Troop...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for LINZESS 145 MCG capsules (30-count units) on August 6, 2025, with a ceiling value of $5,326.68. This non-set-aside, competitively awarded contract utilizes firm fixed pricing and is scheduled for completion by August 7, 2025. The order will be fulfilled from AmerisourceBergen's corporate office located in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger Indefinite...
- The Defense Logistics Agency awarded a delivery order valued at $10,909.98 to AmerisourceBergen Drug Corp for LINZESS 72 mcg capsules (30-count units) on August 19, 2025, with an ultimate completion date of August 20, 2025. This competitively awarded, firm fixed-price contract involves no set-aside designation and will be performed at the vendor's corporate office location in Conshohocken, Pennsylvania. The delivery order represents a child contract under AmerisourceBergen Drug Corp's larger...
- The Defense Logistics Agency awarded a $20,281.88 firm fixed-price delivery order to AmerisourceBergen Drug Corp for the supply of LINZESS 145 MCG capsules (30-count units) with an ultimate completion date of August 18, 2025. This non-set-aside competitive award was issued on August 15, 2025, and will be performed at the contractor's corporate office location in Conshohocken, Pennsylvania. AmerisourceBergen Drug Corp, a major pharmaceutical distributor and critical federal medical procurement...
- The Defense Logistics Agency awarded a delivery order valued at $1,909.80 to AmerisourceBergen Drug Corp for Linzess 72 microgram capsules (30-count units) on September 3, 2025, with an ultimate completion date of September 4, 2025. This competitive award, which carries no set-aside designation, represents a firm fixed-price delivery order for pharmaceutical supply to support federal medical procurement needs. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in...
- The Defense Logistics Agency awarded a $4,629.78 firm fixed-price delivery order to AmerisourceBergen Drug Corp for 30 capsules of Linzess 145 micrograms on September 10, 2025, with completion expected by September 11, 2025. This non-set-aside award represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, a comprehensive $999.99 billion pharmaceutical prime vendor agreement valued through December 2026. The product will...
- The Defense Logistics Agency awarded a $6,580.09 firm fixed price delivery order to AmerisourceBergen Drug Corp for LINZESS 145 MCG capsules (30-count units) with an ultimate completion date of September 9, 2025. This non-set-aside competitive award was issued to AmerisourceBergen's Corporate Office, headquartered in Conshohocken, Pennsylvania, which serves as a critical pharmaceutical distributor for federal medical procurement. The delivery order represents a single transaction under...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 8, 2025, for the supply of Linzess 145 mcg capsules (30-count units) with a ceiling value of $4,586.15. This is a firm fixed-price delivery order with no set-aside designation, issued under competitive procurement procedures. The order is due for completion by September 9, 2025, and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery...
- SPE2DB20D3303Indefinite Delivery Contract
- SPE2DB20D3303-SPE2DB25FA2ZKDelivery Order
The Defense Logistics Agency awarded a $1,116.04 firm fixed price delivery order to AmerisourceBergen Drug Corp for LINZESS 145 microgram capsules (30-count unit of use packaging) on August 26, 2025, with an ultimate completion date of August 27, 2025. This non-competitive delivery order is issued under the vendor's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a $999,999,999.00 comprehensive global pharmaceutical support vehicle running through December 2026. The contract will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order represents a routine pharmaceutical procurement supporting military and federal healthcare systems through DLA's established pharmaceutical supply chain. LINZESS is a prescription medication used to treat irritable bowel syndrome and chronic idiopathic constipation, and its procurement through the DLA prime vendor system ensures consistent, competitively-priced access to essential medications for defense and veteran healthcare programs. AmerisourceBergen's status as a primary pharmaceutical distributor to federal medical supply chains enables efficient fulfillment of varied therapeutic medication requirements across the Defense Health Agency and related government healthcare entities.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $1.1k | 8/26/25 |